I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...

New research published in Brain, Behavior, and Immunity provides evidence that alcohol use disorder triggers a distinct type ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...

ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision ...

PRINCETON, N.J.--(BUSINESS WIRE)--Kanvas Biosciences, a full-stack spatial biology company, today announced results from a clinical trial of fecal microbiota transplantation (FMT) and anti-PD-1 ...

Immorta Bio today announced the publication of a landmark preclinical study in the Journal of Translational Medicine demonstrating that its novel immunotherapy, SenoVax(TM), dramatically reduces ...

Immunitybio Inc ( (IBRX)) has released its Q3 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors. ImmunityBio, Inc. is a biotechnology company focused on ...

In a study published in Nature Ecology and Evolution, scientists show that the SAMD9 and SAMD9L genes, key players in antiviral immunity in humans and involved in rare genetic diseases, share ...

-- Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors -- Matthew Baker appointed as CEO -- Laigo Bio's SureTAC (TM) membrane protein degradation ...

Promise Bio Ltd. emerged from stealth with $8.3 million in seed investment for its precision medicine platform, which addresses immune-mediated diseases. The funding will be used to accelerate the ...